{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ATC|BLOOD AND BLOOD FORMING ORGANS|ANTIHEMORRHAGICS" in comments (approximate match)
Status:
US Approved Rx
(2008)
First approved in 1999
Class:
PROTEIN
Status:
US Approved Rx
(1997)
First approved in 1997
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 1990
Source:
ALPHANINE SD by GRIFOLS BIOLOGICALS LLC
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
First approved in 1947
Class:
PROTEIN
Status:
US Previously Marketed
Source:
TRASYLOL by BAYER HLTHCARE
(1993)
Source URL:
First approved in 1993
Source:
TRASYLOL by BAYER HLTHCARE
Source URL:
Class:
PROTEIN
Status:
First approved in 1946
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02552576: Phase 4 Interventional Completed Von Willebrand Disease
(2015)
Source URL:
First approved in 2009
Source:
BLA125251
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04269954: Phase 4 Interventional Unknown status Cerebral Venous Sinus Thrombosis
(2020)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
